Trials / Conditions / Relative Bioavailability

Relative Bioavailability

11 registered clinical trials studyying Relative Bioavailability.

Status	Trial	Sponsor	Phase
Completed	A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml) NCT06025344	TrippBio, Inc.	Phase 1
Completed	An Evaluation of the Effect of Food on the PK of a Novel PanCytoVir™ Suspension (100mg/ml), in Healthy, Adult NCT06025318	TrippBio, Inc.	Phase 1
Completed	Bioavailability of Tebipenem (SPR994) Crushed Tablet NCT05296382	Hartford Hospital	Phase 1
Completed	Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations NCT04814472	Blade Therapeutics	Phase 1
Completed	A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations NCT04686669	Forendo Pharma Ltd	Phase 1
Completed	A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (EL NCT03934333	AstraZeneca	Phase 1
Completed	To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufactu NCT03483259	Hutchison Medipharma Limited	Phase 1
Unknown	Relative Bioavailability Among Different Eutropin Formulations NCT03154840	LG Chem	Phase 1
Completed	Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When D NCT02359045	AstraZeneca	Phase 1
Completed	Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects NCT02052349	AbbVie	Phase 1
Completed	A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dos NCT01911741	Astellas Pharma Europe B.V.	Phase 1